News
DXCM
68.16
-2.85%
-2.00
Robinhood, AppLovin, Rivian and More Stocks With Earnings This Week
Benzinga · 1d ago
Weekly Report: what happened at DXCM last week (0202-0206)?
Weekly Report · 2d ago
Dexcom Stelo AI Update Links Glucose Data To Everyday Metabolic Health
Simply Wall St · 4d ago
August 21st Options Now Available For DexCom (DXCM)
NASDAQ · 4d ago
DexCom Expands Stelo AI Tools As It Seeks Stickier CGM Users
Simply Wall St · 5d ago
A Look Into DexCom Inc's Price Over Earnings
Benzinga · 5d ago
Piper Sandler Remains a Buy on Dexcom (DXCM)
TipRanks · 5d ago
STELO ADDS ENHANCED SMART MEAL LOGGING FEATURES AS DEXCOM CONTINUES TO TRANSFORM PERSONAL GLUCOSE MANAGEMENT
Reuters · 6d ago
Weekly Report: what happened at DXCM last week (0126-0130)?
Weekly Report · 02/02 09:38
What DexCom (DXCM)'s Strong Q4 Beat and Margin Guidance Means For Shareholders
Simply Wall St · 02/02 06:16
DexCom Faces Split Analyst Views As Competition Pressures Core CGM Markets
Simply Wall St · 01/31 13:18
Assessing DexCom (DXCM) Valuation After Barclays Downgrade On Rising CGM Competition
Simply Wall St · 01/30 02:41
HALPER SADEH LLC ENCOURAGES DEXCOM, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
PR Newswire · 01/29 22:00
Price Over Earnings Overview: DexCom
Benzinga · 01/29 15:00
3 Former Stock Picks Are Quietly Flashing Buy Signals Again
Barron‘s · 01/29 04:33
Top performing healthcare stocks in the past month
Seeking Alpha · 01/28 16:30
Is Dexcom (DXCM) Pricing Reflect Long Term Potential After Continuous Glucose Monitoring Focus?
Simply Wall St · 01/28 10:24
DexCom Inc. to Announce Q4 and Fiscal Year 2025 Results
Reuters · 01/27 17:24
DEXCOM SCHEDULES FOURTH QUARTER AND FISCAL YEAR 2025 EARNINGS RELEASE AND CONFERENCE CALL FOR FEBRUARY 12, 2026 AT 4:30 P.M. EASTERN TIME.
Reuters · 01/27 13:30
INVESTOR NOTICE: Kaskela Law Firm Announces Stockholder Investigation of DexCom, Inc. (NASDAQ: DXCM) and Encourages Long-Term Investors to Contact the Firm
PR Newswire · 01/27 13:00
More
Webull provides a variety of real-time DXCM stock news. You can receive the latest news about Dexcom Inc through multiple platforms. This information may help you make smarter investment decisions.
About DXCM
DexCom, Inc. is a medical device company. The Company is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6, Dexcom G7, Stelo, Dexcom Share, and Dexcom ONE. The Company enables people to take control of health through innovative biosensing technology. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes.